Schering-Plough Corporation: PharmaVitae Profile

Content

• Chapter 1 Executive Summary
  • Key Findings
  • Historical And Forecast Ethical Sales Performance
  • Therapeutic Strategy
  • Launch And Expiry Outlook
  • Externalization, Geographic And Molecule Type Strategies
  • Externalization Strategy
  • Geographic Strategy
  • Molecule Type Strategy
  • Swot Analysis
  • Strengths
  • Weaknesses
  • Opportunities
  • Threats
• Chapter 2 Corporate History
  • Key Findings
  • Background
  • Key Corporate Developments
  • M&A History
  • Schering Corp Merger With Plough Corp
  • Neogenesis
  • Organon Biosciences
  • M&A Strategy
  • Current Corporate Structure
  • Ethical Pharmaceuticals
  • Consumer Health
  • Animal Health
  • Current Management Team
• Chapter 3 Historical Performance
  • Key Findings
  • Introduction
  • Revenue And Growth Rate Analysis, 2001-06
  • Revenue And Growth Rate Vs. Peer Set
  • Product Analysis, 2001-06
  • Growth Drivers
  • Organon M&A
  • Zetia/Vytorin
  • Remicade
  • Growth Resistors
  • Claritin
  • Operating Revenue And Cost Analysis, 2001-06
  • Operating Revenue/Cost Analysis
• Chapter 4 Forecast Performance
  • Key Findings
  • Introduction
  • Revenue And Growth Rate, 2006-12
  • Product Analysis, 2006-12
  • Growth Drivers
  • Zetia/Vytorin
  • Mff258
  • Asenapine
  • Nasonex
  • Remicade
  • Sugammadex
  • Growth Resistors
  • Clarinex
  • Rebetol
  • Therapy Area Analysis, 2006-12
  • Cv & Hematology
  • Cns
  • Respiratory
  • Immunology & Inflammation
  • Urology & Sexual Health
  • Therapy Area Focus
  • Launches And Expiries Analysis, 2006-12
  • Launch Portfolio
  • Core Portfolio
  • Expiry Portfolio
  • Launch/Core/Expiry Configuration
  • Externalization Analysis, 2006-12
  • Geographic Analysis, 2006-12
  • Molecule Type Analysis, 2006-12
• Chapter 5 Key Products And Competitors
  • Key Findings
  • Overview
  • Cardiovascular
  • Zetia/Vytorin
  • Overview
  • Sales Forecast
  • News Flow
  • Competitive Landscape
  • Current Market Assessment
  • Antidyslipidemic Market Overview
  • Future Market Assessment
  • Respiratory
  • Nasonex/Asmanex (Mometasone Franchise)
  • Overview
  • Sales Forecast
  • News Flow
  • Current Market Assessment
  • Infectious Disease
  • Intron Franchise
  • Overview
  • Sales Forecast
  • News Flow
  • Noxafil
  • Overview
  • Sales Forecast
  • News Flow
  • Urology & Sexual Health
  • Nuvaring
  • Overview
  • Sales Forecast
  • News Flow
  • Competitive Landscape
  • Another Strong Year For Organon's Number One Growth Driver
  • Promotional Drive Remains Key Factor In Nuvaring's Uptake
  • Contraceptive Market Overview
  • Future Market Assessment
  • Puregon
  • Overview
  • Sales Forecast
  • News Flow
  • Competitive Landscape
  • Current Market Assessment
  • Future Market Assessment
  • Cns
  • Asenapine
  • Overview
  • Sales Forecast
  • News Flow
  • Competitive Landscape
  • Future Market Assessment
  • Sugammadex
  • Overview
  • Sales Forecast
  • News Flow
  • Competitive Landscape
  • Clinical Trial Progression
  • Future Market Assessment
  • Oncology
  • Temodar
  • Overview
  • Sales Forecast
  • News Flow
  • Immunology & Inflammation
  • Remicade
  • Overview
  • Sales Forecast
  • News Flow
  • Golimumab
  • Overview
  • Sales Forecast
  • R&D Pipeline
• Chapter 6 Appendix
  • Ims Vs. Company-Reported Data Reconciliation
  • References
  • Abbreviations
  • Exchange Rates
• List Of Tables
  • Table 1: Schering-Plough Corporate Executive Committee
  • Table 2: Peer Set Overview
  • Table 3: Operating Revenue/Cost Analysis ($M), 2001-06
  • Table 4: Operating Cost Ratio Analysis (% Of Total Revenues), 2001-06
  • Table 5: Product Portfolio Overview, Sales ($M), 2006-12
  • Table 6: Therapy Area Overview, Sales ($M), 2006-12
  • Table 7: Launch Portfolio Overview, Sales ($M), 2006-12
  • Table 8: Core Portfolio Overview, Sales ($M), 2006-12
  • Table 9: Expiry Portfolio Overview, Sales ($M), 2006-12
  • Table 10: Externally Developed Portfolio ($M), 2006-12
  • Table 11: Molecule Type Overview, Sales ($M), 2006-12
  • Table 12: Key Products Overview
  • Table 13: Zetia/Vytorin: Overview
  • Table 14: Zetia/Vytorin: Sales Forecast ($M), 2006-12
  • Table 15: Zetia/Vytorin: News Flow
  • Table 16: Antidyslipidemic Market Overview, 7mm Sales ($M), 2006
  • Table 17: Nasonex: Overview
  • Table 18: Asmanex: Overview
  • Table 19: Nasonex: Sales Forecast ($M), 2006-12
  • Table 20: Asmanex: Sales Forecast ($M), 2006-12
  • Table 21: Nasonex/Asmanex: News Flow
  • Table 22: Intron Franchise: Overview
  • Table 23: Rebetol: Overview
  • Table 24: Intron A/Peg-Intron: Sales Forecast ($M), 2006-12
  • Table 25: Rebetol: Sales Forecast ($M), 2006-12
  • Table 26: Intron Franchise: News Flow
  • Table 27: Noxafil: Overview
  • Table 28: Noxafil Sales Forecast ($M), 2006-12
  • Table 29: Noxafil: News Flow
  • Table 30: Nuvaring: Overview
  • Table 31: Nuvaring: Sales Forecast ($M), 2006-12
  • Table 32: Nuvaring: News Flow
  • Table 33: Organon's Non-Dtc Marketing Expenditure In 2006
  • Table 34: Top 10 Contraceptives In 2006 (7mm)
  • Table 35: Puregon/Follistim: Overview
  • Table 36: Puregon/Follistim: Sales Forecast ($M), 2006-12
  • Table 37: Puregon/Follistim: News Flow
  • Table 38: Asenapine: Overview
  • Table 39: Asenapine: Sales Forecast ($M), 2006-12
  • Table 40: Asenapine: News Flow
  • Table 41: Sugammadex: Overview
  • Table 42: Sugammadex: Sales Forecast ($M), 2006-12
  • Table 43: Sugammadex: News Flow
  • Table 44: Temodar/Temodal: Overview
  • Table 45: Temodar: Sales Forecast ($M), 2005-11
  • Table 46: Temodar: News Flow
  • Table 47: Remicade: Overview
  • Table 48: Remicade: Sales Forecast ($M), 2006-12
  • Table 49: Remicade: News Flow
  • Table 50: Golimumab: Overview
  • Table 51: Golimumab: Sales Forecast ($M), 2006-12
  • Table 52: Schering-Plough's R&D Pipeline (Phase I-Registration)
  • Table 53: Schering-Plough's Indication Broadening Pipeline (Phase I-Registration)
  • Table 54: Exchange Rates, 2006
• List Of Figures
  • Figure 1: Historical And Forecast Ethical Sales Performance (% Cagr), Schering-Plough And Big Pharma Peer Set
  • Figure 2: Therapeutic Focus Vs. Big Pharma Peer Set (%), 2006
  • Figure 3: Launch, Core And Expiry, Absolute Sales Growth, 2006-12 (Sales As % Of 2006 Sales), Schering-Plough
  • Figure 4: Launch, Core And Expiry, Absolute Sales Growth, 2006-12 (Sales As % Of 2006 Sales), Big Pharma
  • Figure 5: Molecule Type, Externalization And Geographic Market Dependency (%) Vs. Peer Set, 2006
  • Figure 6: Molecule Type, Externalization And Geographic Market Dependency (%) Vs. Peer Set, 2012
  • Figure 7: Swot Analysis Of Schering-Plough
  • Figure 8: Therapy Area Focus, % Total Sales, 2006
  • Figure 9: Growth Driver By Company, Sales ($M), 2006-12
  • Figure 10: Ethical Sales By Company, Sales ($M), 2006-12
  • Figure 11: Current Corporate Structure
  • Figure 12: Revenue & Growth Rate (Ethical Sales) ($M), 2001-06
  • Figure 13: Ethical Revenue ($M) And Growth Rate (%) Vs. Peer Set, 2001-06
  • Figure 14: Growth Drivers/Resistor Products Of Historical Revenue Performance ($M), 2001-06
  • Figure 15: Operating Revenue/Cost Analysis ($M), 2001-06
  • Figure 16: Operating Cost Ratio Analysis (% Of Total Revenues), 2001-06
  • Figure 17: Ethical Revenue ($M) And Growth Rate (%), 2006-12
  • Figure 18: Top Five Products By Sales ($M), 2006
  • Figure 19: Top Five Products By Sales ($M), 2012
  • Figure 20: Growth Drivers And Resistors By Product, 2006-12
  • Figure 21: Key Strategic Products, Sales ($M), 2006-12
  • Figure 22: Ethical Sales By Therapy Area ($M), 2006-12
  • Figure 23: Growth Drivers And Resistors By Therapy Area (%), 2006-12
  • Figure 24: Ethical Sales By Therapy Area ($M), 2006-12
  • Figure 25: Therapy Area Focus Compared With Peer Set (% Total Ethical Sales), 2006
  • Figure 26: Therapy Area Focus Compared With Peer Set (% Total Ethical Sales), 2012
  • Figure 27: Launch Schedule, Sales ($M), 2006-12
  • Figure 28: Core Products Sales Growth ($M), 2006-12
  • Figure 29: Expiry Schedule, Sales ($M), 2006-12
  • Figure 30: Launch, Core And Expiry, Sales ($M), 2006-12
  • Figure 31: Launch, Core And Expiry, Absolute Sales Growth, 2006-12 (Sales As % Of 2006 Sales), Schering-Plough
  • Figure 32: Launch, Core And Expiry, Absolute Sales Growth, 2006-12 (Sales As % Of 2006 Sales), Peer Set
  • Figure 33: Externalization Dependency, Sales ($M), 2006-12
  • Figure 34: Growth Drivers And Resistors, Externally Vs. Internally Discovered Products, Sales ($M), 2006-12
  • Figure 35: Externalization Dependency Vs. Peer Set, % Total Sales, 2006
  • Figure 36: Externalization Dependency Vs. Peer Set, % Total Sales, 2012
  • Figure 37: Geographical Sales Breakdown ($M), 2006-12
  • Figure 38: Growth Drivers And Resistors By Geography, Sales ($M), 2006-12
  • Figure 39: Us Dependency Vs. Peer Set, % Total Sales, 2006
  • Figure 40: Us Dependency Vs. Peer Set, % Total Sales, 2012
  • Figure 41: Molecule Type Sales Breakdown ($M), 2006-12
  • Figure 42: Growth Drivers And Resistors By Molecule Type, Sales ($M), 2006-12
  • Figure 43: Biologics Dependency Vs. Peer Set, % Total Sales, 2006
  • Figure 44: Biologics Dependency Vs. Peer Set, % Total Sales, 2012
  • Figure 45: Top Five Antidyslipidemic Drug Quarterly Sales ($M), 7mm, 2006
  • Figure 46: Quarterly Sales($M) Of Top Five Contraceptives, 2006
  • Figure 47: Puregon Vs. Gonal-F, Quarterly Sales ($M), 2003-06
  • Figure 48: Ims Vs. Company-Reported Ethical Sales Discrepancy ($M), 2006
  • Figure 49: Ims Vs. Company-Reported Ethical Sales Forecast Growth Rates (%), 2006-12